by MM360 Staff | May 28, 2025 | Publications
Front Med (Lausanne). 2025 May 13;12:1575914. doi: 10.3389/fmed.2025.1575914. eCollection 2025. ABSTRACT INTRODUCTION: Multiple myeloma (MM) is a plasma cell malignancy comprising 10% of hematologic cancers, associated with bone marrow dysfunction and organ damage....
by MM360 Staff | May 27, 2025 | Publications
Blood Cancer J. 2025 May 26;15(1):104. doi: 10.1038/s41408-025-01312-x. ABSTRACT While observation is the current standard of care for smoldering multiple myeloma (sMM), emerging evidence suggests that early therapeutic intervention may delay progression and improve...
by MM360 Staff | May 24, 2025 | Publications
Clin Lymphoma Myeloma Leuk. 2025 Apr 3:S2152-2650(25)00105-3. doi: 10.1016/j.clml.2025.03.013. Online ahead of print. ABSTRACT PURPOSE: The increasing use of single-arm and nonrandomized trial designs in oncology aims to expedite patient access to novel treatments. To...
by MM360 Staff | May 17, 2025 | Publications
Syst Rev. 2025 May 16;14(1):113. doi: 10.1186/s13643-025-02804-4. ABSTRACT BACKGROUND: Daratumumab (Dara)-based regimens have been investigated in randomized controlled trials (RCTs) involving patients with newly diagnosed and previously untreated multiple myeloma...
by MM360 Staff | May 13, 2025 | Publications
Int J Hematol. 2025 May 13. doi: 10.1007/s12185-025-03998-y. Online ahead of print. ABSTRACT BACKGROUND: Sarcopenia, characterized by skeletal muscle loss, is increasingly recognized as a predictor of poor outcomes in hematologic malignancies. This study evaluated the...
by MM360 Staff | May 12, 2025 | Publications
Front Immunol. 2025 Apr 25;16:1565407. doi: 10.3389/fimmu.2025.1565407. eCollection 2025. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a hematological malignancy with limited treatment options for patients with relapsed/refractory MM (RRMM). Teclistamab, a B-cell...
